Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of RYLAZE described in the WARNINGS AND PRECAUTIONS reflect exposure in 167 patients administered RYLAZE intramuscularly at various dosages when used in combination with chemotherapy in study JZP458-201 [see Clinical Studies (14)]. These patients received a median of 4 courses of RYLAZE (range: 1-15 courses); 65% of patients received at least four courses.
The safety of RYLAZE described below and in Table 3 was evaluated in study JZP458-201, a multi-cohort study. Patients received RYLAZE administered intramuscularly at dosages of 25 mg/m2 on Monday, Wednesday, and Friday or 25 mg/m2 on Monday and Wednesday, and 50 mg/m2 on Friday, for 6 doses as a replacement for a single dose of pegaspargase as a component of multi-agent chemotherapy [see Clinical Studies (14)]. The patients had a median age of 11 years (range: 1‑25 years); the majority of patients were male (57%) and White (68%). The patients received a median of 4 courses of RYLAZE (range: 1-14 courses); 65% of patients received at least four courses.
A fatal adverse reaction (infection) occurred in 1 patient treated with the RYLAZE 25/25/25 mg/m2 dosage. Serious adverse reactions occurred in 60% of patients who received the recommended dosages of RYLAZE. The most frequent nonhematological serious adverse reactions (in ≥ 5% of patients) were febrile neutropenia, infection, drug hypersensitivity, pyrexia, nausea, dehydration, stomatitis, acute kidney injury, pancreatitis, diarrhea, and viral infection. Permanent discontinuation due to an adverse reaction occurred in 10% of patients who received RYLAZE intramuscularly at the recommended dosages. Adverse reactions resulting in permanent discontinuation included pancreatitis (5%), drug hypersensitivity (4%), and infection (1%).
All patients treated with the recommended dosages of RYLAZE as a component of multi-agent chemotherapy experienced neutropenia, anemia, or thrombocytopenia. The most common nonhematological adverse reactions (incidence > 20%) in patients were abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, and hypokalemia. Table 3 shows the common adverse reactions occurring in at least 15% of the patients.
Table 3: Adverse Reactions (≥ 15% Incidence) in Patients Receiving RYLAZE as a Component of Multi-Agent Chemotherapy in Study JZP458-201Adverse Reaction | RYLAZE 25/25/25 mg/m2 Intramuscular Dosagea (N = 33) | RYLAZE 25/25/50 mg/m2 Intramuscular Dosagea (N = 51) |
All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) |
Abnormal liver test*# | 70 | 18 | 75 | 27 |
Musculoskeletal pain* | 45 | 6 | 35 | 4 |
Nausea* | 45 | 9 | 47 | 8 |
Fatigue* | 36 | 18 | 22 | 18 |
Headache | 36 | 0 | 22 | 0 |
Infection*b | 36 | 15 | 27 | 17 |
Febrile neutropenia | 30 | 30 | 27 | 27 |
Pyrexia | 30 | 6 | 20 | 0 |
Hemorrhage* | 24 | 0 | 27 | 6 |
Stomatitis | 24 | 12 | 27 | 4 |
Abdominal pain* | 21 | 0 | 25 | 2 |
Decreased appetite | 21 | 6 | 27 | 6 |
Drug hypersensitivity* | 21 | 6 | 24 | 2 |
Hyperglycemia | 21 | 3 | 12 | 4 |
Diarrhea* | 18 | 6 | 25 | 4 |
Tachycardia* | 18 | 0 | 16 | 2 |
Cough | 15 | 0 | 14 | 0 |
Dehydration | 15 | 9 | 12 | 6 |
Insomnia | 15 | 0 | 4 | 0 |
Peripheral neuropathy* | 15 | 0 | 6 | 0 |
Pancreatitis*# | 12 | 0 | 22 | 10 |
Hypokalemia | 9 | 3 | 22 | 8 |
* Includes grouped terms: Abnormal liver test: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, transaminases increased; Musculoskeletal pain: arthralgia, back pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, pain in extremity; Nausea: nausea, vomiting; Fatigue: fatigue, asthenia; Infection: sepsis, upper respiratory tract infection, enterocolitis infectious, skin infection, bacteremia, paronychia, pneumonia, otitis externa, soft tissue infection, abdominal infection, conjunctivitis, device related infection, folliculitis, lymph gland infection, necrotizing fasciitis, perirectal abscess, peritonsillar abscess, sinusitis, subcutaneous abscess, wound infection; Drug hypersensitivity: drug hypersensitivity, rash, infusion related reaction, lip swelling, periorbital edema, throat irritation, urticaria, dry skin, eczema, erythema, hand dermatitis, rash maculo-papular, rash papular; Hemorrhage: contusion, epistaxis, catheter site hemorrhage, petechiae, hematochezia, menorrhagia, mouth hemorrhage, increased tendency to bruise, rectal hemorrhage; Abdominal pain: abdominal pain, abdominal pain upper; Diarrhea: diarrhea, colitis; Tachycardia: sinus tachycardia, tachycardia; Peripheral neuropathy: peripheral motor neuropathy, neuropathy peripheral, peripheral sensory neuropathy; Pancreatitis: pancreatitis, pancreatitis acute, amylase increased, lipase increased.
*Includes adverse event terms and laboratory abnormalities
Grading is based on Common Terminology Criteria for Adverse Events version 5.0.
a RYLAZE was administered as a component of multi-agent chemotherapy regimens on a Monday, Wednesday, and Friday schedule.
b Does not include the following fatal adverse reactions: infection (N=1).
Clinically relevant adverse reactions in < 15% of patients who received RYLAZE in combination with chemotherapy included:
Gastrointestinal disorders: Abdominal discomfort, abdominal distension, constipation, gastritis
General disorders and administration site conditions: Infusion site reaction, injection site reaction, pain
Infections and infestations: Viral infection, bacterial infection, fungal infection
Investigations: Antithrombin III decreased, blood cholesterol increased, blood fibrinogen decreased, activated partial thromboplastin time prolonged
Metabolism and nutrition disorders: Acidosis, hyperammonemia, hyperphosphatemia, hypertriglyceridemia, hypoglycemia
Musculoskeletal and connective tissue disorders: Bone pain, muscular weakness, muscle spasms
Nervous system disorders: Paresthesia, dizziness, gait disturbance, hyperammonemic encephalopathy
Psychiatric disorders: Agitation, anxiety, irritability
Respiratory, thoracic, and mediastinal disorders: Acute respiratory distress syndrome, pulmonary edema
Renal and urinary disorders: Acute kidney injury
Skin and subcutaneous disorders: Pruritus
Vascular disorders: Hypertension, hypotension, thrombosis